Chen W, et al. - In patients with type 2 diabetes mellitus (T2DM) with or without prevalent kidney disease, researchers tested the safety and effectiveness of Sodium-Glucose cotransporter 2 inhibitors (SGLT2is) on kidney outcomes. To evaluate the effectiveness and safety of SGLT2is treatment vs placebo in T2DM, PubMed, Web of science, Embase and the Cochrane Library were systematically searched for randomized controlled trials (RCTs). The results of this systematic review and meta-analysis indicate that SGLT2is slowed estimated glomerular filtration rate (eGFR) decline, lowered albuminuria progression, improved adverse renal endpoints and reduced all-cause mortality, but increased risk of genital infections compared to placebo in T2DM. They suggested that the indication of consistent renal benefits across baseline eGFR levels can enable additional people to benefit from SGLT2is therapy.